Abstract
PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 443-451 |
| Number of pages | 9 |
| Journal | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Cite this
}
High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. / Azad, Arun; Chionh, Fiona; Scott, Andrew M.; Lee, Szeting T.; Berlangieri, Sam U.; White, Shane; Mitchell, Paul L.
In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, Vol. 12, No. 4, 08.2010, p. 443-451.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.
AU - Azad, Arun
AU - Chionh, Fiona
AU - Scott, Andrew M.
AU - Lee, Szeting T.
AU - Berlangieri, Sam U.
AU - White, Shane
AU - Mitchell, Paul L.
PY - 2010/8
Y1 - 2010/8
N2 - PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.
AB - PURPOSE: We evaluated whether 18F-FDG-PET altered stage classification, management, and prognostic stratification of newly diagnosed small cell lung cancer (SCLC). PROCEDURES: We identified 46 consecutive patients undergoing staging positron emission tomography for SCLC from 1993-2008 inclusive. Updated survival data from the state Cancer Registry was available on 42 of 46 patients. RESULTS: PET altered stage classification in 12 of 46 (26%) patients. PET altered treatment modality in nine patients, and the target mediastinal radiation field in another three patients. Therefore, PET altered management in 12 of 46 (26%) patients. Patients with limited disease (LD) on pre-PET staging had significantly longer overall survival (OS) than those upstaged to extensive disease (ED; median 18.6 months versus 5.7 months; log-rank p < 0.0001). In patients with ED on pre-PET staging, those downstaged to LD by PET had significantly longer OS than those with ED on PET (median 10.9 months versus 5.9 months; log-rank p = 0.037). CONCLUSION: PET had a major impact on stage classification, management, and prognostic stratification of newly diagnosed SCLC.
UR - http://www.scopus.com/inward/record.url?scp=78149277688&partnerID=8YFLogxK
U2 - 10.1007/s11307-009-0295-z
DO - 10.1007/s11307-009-0295-z
M3 - Article
C2 - 19921339
AN - SCOPUS:78149277688
VL - 12
SP - 443
EP - 451
JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
SN - 1536-1632
IS - 4
ER -